Abstract
Introduction: A promising compound for the treatment of inflammatory periodontal diseases is benzofuracaine (BFC) .BFC has pronounced anti-inflammatory, analgesic, reparative, hypoglycemic and other effects. Objective: To assess the influence of benzofuracaine on experimental periodontitis and to study its antidiabetic activity and molecular mech-anisms of action
 Materials and methods: The work was performed on 232 white nonlinear rats of both sexes and 55 male mice. To assess the effect of BFС on experimental periodontitis, the amount of gingival fluid (AGF) was determined, an in-depth morphofunctional study of periodontal tissues was conducted, as well as the study of the biochemical composition of the gingiva and blood. Antidiabetic properties were studied using the glucose tolerance test (GTT), as well as the as-sessment of endothelium-dependent vasodilation and transmembrane K+-currents on an isolated aortic segment of ratswith streptozotocin-induced diabetes mellitus (DM).
 Results and discussion: In experimental periodontitis, BFC improves the morphological picture and decreases AGF, in-creases the level of blood microcirculation in the attached gingiva, has a normalizing effect on the prekallikrein-kallikrein system, reduces the synthesis of bradykinin, proinflammatory cytokines and PGE2, increases the level of VEGF, reduces the level of endothelin-1, increases the ATP content and NADH-ubiquinone-reductase activity, exhibits antioxidant properties,reduces the content of nitrosothiols and NO metabolites (NO2/NO3), increases the level of transferrin; when conducting a
 glucose tolerance test in mice, it reduces the level of glucose in the blood, but in this respect is inferior to glibenclamide, has a hypoglycemic effect in the early stages of diabetes (30 days), tends to restore endothelium-dependent dilatation of smooth muscle cells (SMC) of the aorta and does not affect the functioning of the K+-channels of the aortic SMC.
 Conclusion: BFС is an effective drug for the treatment of periodontitis and can be recommended for further preclinical and clinical studies.
Highlights
ObjectivesTo assess the influence of benzofuracaine on experimental periodontitis and to study its antidiabetic activity and molecular mechanisms of action
A promising compound for the treatment of inflammatory periodontal diseases is benzofuracaine (BFC)
In case of healthy periodontium, BFC reduces the flow of erythrocytes and its variability in the capillary bed of attached gingiva (AG) of lower incisors in rats; at the sme time while vasomotor activity remains stable compared to the baseline, which may be due to an increase in total peripheral vascular resistance
Summary
To assess the influence of benzofuracaine on experimental periodontitis and to study its antidiabetic activity and molecular mechanisms of action
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
